RT @RichardPAConway: ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared
Tweet Content
ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared to TNFi . Abstr#1940 #ACR21 @RheumNow https://t.co/uc2k5EaiRq
Show on Archive Page
On
Display in Search Results
On
PDQ
Off